Homepage > Company > Media > Pharma News > 2020 > U.S. FDA puts early-stage trial of Altimmune's COVID-19 vaccine on hold

U.S. FDA puts early-stage trial of Altimmune's COVID-19 vaccine on hold

(Reuters) - Altimmune Inc said on Wednesday the U.S. Food and Drug Administration had put a clinical hold on its application to begin human testing of its single-dose COVID-19 vaccine, AdCOVID.

The FDA sought additional data on the vaccine candidate’s chemistry, manufacturing and controls, and asked the company for some protocol changes.

Altimmune said it has responded to the agency’s letter received on Dec. 22.

The company said it does not see the FDA’s hold to have a huge impact on the timeline of the overall clinical development of AdCOVID.

DECEMBER 24, 2020

https://www.reuters.com/

Read also

Merck gains rights to LaNova’s PD-1/VEGF bispecific antibody in deal worth over $3.2bn

Merck & Co – known as MSD outside the US and Canada – has entered into an exclusive global licensing agreement worth over $3.2bn to advance LaNova Medicines’ investigational PD-1/VEGF bispecific...

Rectify Pharma Presents Preclinical Data Supporting Development of Lead Candidate RTY-694 at The Liver Meeting® 2024

Rectify Pharmaceuticals, Inc., a biotechnology company developing positive functional modulators (PFMs), small molecule therapeutics that restore and enhance membrane protein function, today ...

Ideaya hires Gilead leader to head up commercialization push

Ideaya Biosciences has made a key hire in anticipation of the launch of its first drug, securing the services of an executive who played a role in the commercialization of Trodelvy and Opdivo.

Silo Pharma discloses ‘promising results’ from preclinical study on SPC-15

Silo Pharma announced promising results from a preclinical study on SPC-15. This new formulation, which targets both the serotonin 5-HT4 receptor, 5-HT4R, and the NMDA receptor, NMDAR, has shown poten...